Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NYHA II-IV Heart Failure~* Left ventricular ejection fraction \< 45%~* Stable heart failure medication~* eGFR by sMDRD formula between 30 and 60 mL/min/1.73m2~Exclusion Criteria:~* Known hypersensitivity to study drug or ACEi~* Concomitant treatment with both ARB and Aldosterone Receptor Antagonist~* Symptomatic Hypotension~* Acute Heart Failure~* History of stroke, acute coronary syndrome, PCI or angioplasty within past 3 months~* Serum potassium \> 5.2 mmol/L~* Right heart failure due to severe pulmonary disease~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Aliskiren (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).